Ditolylguanidine
From Wikipedia, the free encyclopedia
Experimental drug
You can help expand this article with text translated from the corresponding article in German. Click [show] for important translation instructions.
- View a machine-translated version of the German article.
- Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must follow the LLM translation guideline, revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
- Consider adding a topic to this template: there are already 1,986 articles in the main category, and specifying
|topic=will aid in categorization. - Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
- You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is
Content in this edit is translated from the existing German Wikipedia article at [[:de:N,N′-Di-o-tolylguanidin]]; see its history for attribution. - You may also add the template
{{Translated|de|N,N′-Di-o-tolylguanidin}}to the talk page. - For more guidance, see Wikipedia:Translation.
Pharmaceutical compound
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.002.344 Edit this at Wikidata |
| Chemical and physical data | |
| Formula | C15H17N3 |
| Molar mass | 239.322g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
Ditolylguanidine (DTG) is a sigma receptor agonist.[1] It is somewhat[2] selective for sigma receptors, but non-selective between the two sigma receptor subtypes, binding to both σ1 and σ2 with equal affinity.[3] It has neuroprotective [4] and antidepressant effects,[5] and potentiates the effects of NMDA antagonists.[6]
Properties
[edit ]N,N′-Di-o-tolylguanidine is a flammable, white solid that is practically insoluble in water. It decomposes upon heating, potentially releasing nitrogen oxides, carbon monoxide, and carbon dioxide.[7]
Safety Information
[edit ]N,N′-Di-o-tolylguanidine is not itself carcinogenic, but due to the manufacturing process, it may still contain o-toluidine, which is carcinogenic. Therefore, if the o-toluidine content exceeds 0.1 percent, the mixture should be considered carcinogenic.[7]
See also
[edit ]References
[edit ]- ↑ Weber E, Sonders M, Quarum M, McLean S, Pou S, Keana JF (November 1986). "1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs". Proceedings of the National Academy of Sciences of the United States of America. 83 (22): 8784–8788. Bibcode:1986PNAS...83.8784W. doi:10.1073/pnas.83.22.8784 . PMC 387016 . PMID 2877462.
- ↑ "1,3-Di-o-tolylguanidine | C15H17N3". PubChem. U.S. National Library of Medicine. Archived from the original on 2021年01月08日. Retrieved 2017年06月07日.
- ↑ Glennon RA (October 2005). "Pharmacophore identification for sigma-1 (sigma1) receptor binding: application of the "deconstruction-reconstruction-elaboration" approach". Mini Reviews in Medicinal Chemistry. 5 (10): 927–940. doi:10.2174/138955705774329519. PMID 16250835.
- ↑ Katnik C, Guerrero WR, Pennypacker KR, Herrera Y, Cuevas J (December 2006). "Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia". The Journal of Pharmacology and Experimental Therapeutics. 319 (3): 1355–1365. doi:10.1124/jpet.106.107557. PMID 16988055. S2CID 14582181.
- ↑ Skuza G, Rogóz Z (2003). "Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats". Polish Journal of Pharmacology. 55 (6): 1149–1152. PMID 14730114.
- ↑ Monnet FP, Morin-Surun MP, Leger J, Combettes L (November 2003). "Protein kinase C-dependent potentiation of intracellular calcium influx by sigma1 receptor agonists in rat hippocampal neurons". The Journal of Pharmacology and Experimental Therapeutics. 307 (2): 705–712. doi:10.1124/jpet.103.053447. PMID 12975497. S2CID 35397107.
- 1 2 Record of N,N′-Di-o-tolylguanidin in the GESTIS Substance Database of the Institute for Occupational Safety and Health
Stub icon
This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.